


AMENDED CLAIMS

[received by the International Bureau on 17 April 2003 (17.04.03);  
Claims 1 replaced by new claim 1; remaining claims unchanged]

1. A compound having the following formula:



(1)

wherein:

- 5 Ar is a 1-(sulfonyl)-1H-indol-2-yl group;  
the group -OR<sup>O</sup> is independently:

- (a) -OH;  
(b) an ether group; or  
(c) an acyloxy group;

- 10 the bond marked  $\alpha$  is independently:

- (a) a single bond; or  
(b) a double bond;

the bond marked  $\beta$  is independently:

- (a) a single bond; or  
15 (b) a double bond;

each of R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, and R<sup>6</sup>, is independently a ring substituent and is:


- (a) H;  
(b) a monovalent monodentate substituent; or  
(c) a ring substituent which, together with an adjacent ring

- 20 substituent, and together with the ring atoms to which these ring  
substituents are attached, form a fused ring;

and pharmaceutically acceptable salts, esters, amides, solvates,  
hydrates, and protected forms thereof.

- 116 -

2. A compound according to claim 1, wherein  $\alpha$  is independently a double bond and  $\beta$  is independently a double bond, and the compound has the following formula:



- 5 3. A compound according to claim 1, wherein  $\alpha$  is independently a single bond and  $\beta$  is independently a single bond and the compound has the following formula:



- 10 4. A compound according to claim 1, wherein  $\alpha$  is independently a single bond and  $\beta$  is independently a double bond, and the compound has the following formula:



\* \* \*

- 15 5. A compound according to any one of claims 1 to 4, wherein said monovalent monodentate substituent is selected from:

hydroxy (-OH);

halo;

cyano (-CN);

carboxy (-COOH);

azido;

20

- 117 -

ester;

amino, including:

C<sub>1-7</sub>alkyl-amino;amino-C<sub>1-7</sub>alkyl-amino;

5

C<sub>1-7</sub>alkyl, including:halo-C<sub>1-7</sub>alkyl;amino-C<sub>1-7</sub>alkyl;carboxy-C<sub>1-7</sub>alkyl;hydroxy-C<sub>1-7</sub>alkyl;

10

C<sub>5-20</sub>aryl-C<sub>1-7</sub>alkyl;

ether, including:

C<sub>1-7</sub>alkoxy;halo-C<sub>1-7</sub>alkoxy;amino-C<sub>1-7</sub>alkoxy;

15

carboxy-C<sub>1-7</sub>alkoxy;hydroxy-C<sub>1-7</sub>alkoxy;C<sub>5-20</sub>aryl-C<sub>1-7</sub>alkoxy;

acyl, including:

C<sub>1-7</sub>alkyl-acyl;

20

halo-C<sub>1-7</sub>alkyl-acyl;amino-C<sub>1-7</sub>alkyl-acyl;carboxy-C<sub>1-7</sub>alkyl-acyl;hydroxy-C<sub>1-7</sub>alkyl-acyl;C<sub>5-20</sub>aryl-C<sub>1-7</sub>alkyl-acyl;

25

C<sub>5-20</sub>aryl-acyl;C<sub>5-20</sub>aryl;

thiol (-SH); and,

thioether.

30

6. A compound according to any one of claims 1 to 4, wherein said monovalent monodentate substituent is selected from:

-OH;

- 118 -

- F, -Cl, -Br, -I;  
-CN;  
-COOH;  
-N<sub>3</sub>;  
5 -COOMe, -COOEt, -COOtBu, -COOPh, -COOCH<sub>2</sub>Ph;  
  
-NH<sub>2</sub>, -NHMe, -NH<sub>2</sub>Et, -NMe<sub>2</sub>, -NEt<sub>2</sub>;  
piperidino, morpholino, piperazino, N-methyl-piperazino;  
-NH(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -NH(CH<sub>2</sub>)<sub>w</sub>-NHMe, -NH(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -NH(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
10  
-Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu;  
-CH<sub>2</sub>F, -CH<sub>2</sub>Cl, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -C(CF<sub>3</sub>)<sub>3</sub>;  
-(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>w</sub>-NHMe, -(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
-(CH<sub>2</sub>)<sub>w</sub>-COOH;  
15 -(CH<sub>2</sub>)<sub>w</sub>-OH;  
-CH<sub>2</sub>Ph;  
  
-OMe, -OEt, -OnPr, -OiPr, -OnBu, -OiBu, -OsBu, -OtBu;  
-OCH<sub>2</sub>F, -OCH<sub>2</sub>Cl, -OCF<sub>3</sub>, -OCCl<sub>3</sub>, -OCF<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OC(CF<sub>3</sub>)<sub>3</sub>;  
20 -O(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -O(CH<sub>2</sub>)<sub>w</sub>-NHMe, -O(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -O(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
-O(CH<sub>2</sub>)<sub>w</sub>-COOH;  
-O(CH<sub>2</sub>)<sub>w</sub>-OH;  
-OCH<sub>2</sub>Ph;  
  
25 -C(=O)Me, -C(=O)Et, -C(=O)-nPr, -C(=O)-iPr, -C(=O)-nBu, -C(=O)-iBu,  
-C(=O)-sBu, -C(=O)-tBu;  
-C(=O)CH<sub>2</sub>F, -C(=O)CH<sub>2</sub>Cl, -C(=O)CF<sub>3</sub>, -C(=O)CCl<sub>3</sub>, -C(=O)CF<sub>2</sub>CF<sub>3</sub>,  
-C(=O)CH<sub>2</sub>CF<sub>3</sub>, -C(=O)C(CF<sub>3</sub>)<sub>3</sub>;  
-C(=O)(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NHMe, -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>,  
30 -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
-C(=O)(CH<sub>2</sub>)<sub>w</sub>-COOH;  
-C(=O)(CH<sub>2</sub>)<sub>w</sub>-OH;  
-C(=O)CH<sub>2</sub>Ph;

- 119 -

-Ph;

-SH;

5

-SMe, -SEt, -SnPr, -S-iPr, -S-nBu, -S-iBu, -S-sBu, -S-tBu,  
-S-CH<sub>2</sub>-Ph, -S-Ph;

a thioether group derived from cysteine, homocysteine, glutathione, or a peptide comprising the sequence -Cys-(X)<sub>y</sub>-Cys-, where X is an amino acid, and y is an integer from 1 to 6;

10

wherein w is an integer from 1 to 7.

\* \* \*

15

7. A compound according to any one of claims 1 to 6, wherein each of R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, and R<sup>6</sup>, is independently a ring substituent and is:

(a) H; or:

(b) a monovalent monodentate substituent.

20

8. A compound according to any one of claims 1 to 6, wherein R<sup>5</sup> and R<sup>6</sup> are -H; but R<sup>2</sup> and R<sup>3</sup> do not also form a fused ring:




9. A compound according to any one of claims 1 to 6, wherein R<sup>2</sup> and R<sup>3</sup> are -H; but R<sup>5</sup> and R<sup>6</sup> do not also form a fused ring:



25

- 120 -

10. A compound according to any one of claims 1 to 6, wherein  $R^2$  and  $R^6$  are -H:




11. A compound according to any one of claims 1 to 6, wherein  $R^3$  and  $R^5$  are -H:



12. A compound according to any one of claims 1 to 6, wherein  $R^2$ ,  $R^3$ ,  $R^5$  and  $R^6$  are -H:



13. A compound according to any one of claims 1 to 6, wherein  $R^2$ ,  $R^3$ ,  $R^5$  and  $R^6$  are -H;  $\alpha$  is a double bond; and  $\beta$  is a double bond:



14. A compound according to any one of claims 1 to 6, wherein  $R^2$ ,  $R^3$ ,  $R^5$  and  $R^6$  are -H;  $\alpha$  is a single bond; and  $\beta$  is a single bond:



- 121 -

15. A compound according to any one of claims 1 to 6, wherein  $R^2$ ,  $R^3$ ,  $R^5$  and  $R^6$  are -H;  $\alpha$  is a single bond; and  $\beta$  is a double bond:



\* \* \*

5

16. A compound according to any one of claims 1 to 6, wherein
- (a)  $R^2$  and  $R^3$ , together with the ring atoms to which they are attached, form a fused ring;
  - (b)  $R^5$  and  $R^6$ , together with the ring atoms to which they are attached, form a fused ring; or
  - (c) or both (a) and (b).

10

17. A compound according to claim 16, wherein the fused ring, or, if there are two fused rings, one of them, or each of them, is a fused aromatic ring.

15

18. A compound according to claim 16, wherein the fused ring, or, if there are two fused rings, one of them, or each of them, is a fused aromatic ring with 5 or 6 ring atoms.

20

19. A compound according to claim 16, wherein  $R^2$  and  $R^3$  form a fused benzene ring; and  $\beta$  is a double bond:



20. A compound according to claim 19, wherein  $R^5$  and  $R^6$  do not also form a fused ring.

25

- 122 -

21. A compound according to claim 16, wherein  $R^2$  and  $R^3$  form a fused benzene ring;  $\beta$  is a double bond; and  $R^5$  is -H:



22. A compound according to claim 16, wherein  $R^2$  and  $R^3$  form a fused benzene ring;  $\beta$  is a double bond; and  $R^6$  is -H:



23. A compound according to claim 16, wherein  $R^2$  and  $R^3$  form a fused benzene ring;  $\beta$  is a double bond; and  $R^5$  and  $R^6$  are -H:



24. A compound according to claim 16, wherein  $R^2$  and  $R^3$  form a fused benzene ring;  $\beta$  is a double bond;  $R^5$  and  $R^6$  are -H; and  $\alpha$  is a double bond:





- 123 -

25. A compound according to claim 16, wherein  $R^5$  and  $R^6$  form a fused benzene ring; and  $\alpha$  is a double bond:



26. A compound according to claim 25, wherein  $R^2$  and  $R^3$  do not also form a fused ring.

27. A compound according to claim 16, wherein  $R^5$  and  $R^6$  form a fused benzene ring;  $\alpha$  is a double bond; and  $R^3$  is -H:



28. A compound according to claim 16, wherein  $R^5$  and  $R^6$  form a fused benzene ring;  $\alpha$  is a double bond; and  $R^2$  is -H:



\* \* \*


29. A compound according to any one of claims 1 to 28, wherein  $R^O$  is independently:
- (a) -H;
  - (b)  $C_{1-7}$ alkyl,  $C_{3-20}$ heterocyclyl, or  $C_{5-20}$ aryl; and is optionally substituted; or:
  - (c)  $C_{1-7}$ alkyl-acyl,  $C_{3-20}$ heterocyclyl-acyl, or  $C_{5-20}$ aryl-acyl; and is optionally substituted.

- 124 -

30. A compound according to any one of claims 1 to 28, wherein  $R^O$  is independently:
- (b)  $C_{1-7}$ alkyl,  $C_{3-20}$ heterocyclyl, or  $C_{5-20}$ aryl; and is optionally substituted; or:
- (c)  $C_{1-7}$ alkyl-acyl,  $C_{3-20}$ heterocyclyl-acyl, or  $C_{5-20}$ aryl-acyl; and is optionally substituted.
31. A compound according to claim 29 or 30, wherein  $R^O$  is optionally substituted with one more of the following groups:
- hydroxy (-OH);
- halo;
- carboxy (-COOH);
- amino; and,
- $C_{5-20}$ aryl.
32. A compound according to claim 29 or 30, wherein  $R^O$  is unsubstituted.
33. A compound according to any one of claims 1 to 28, wherein  $R^O$  is -H.

\* \* \*

34. A compound according to any one of claims 1 to 33, wherein Ar is a group of the following formula:



wherein:

$R^{SO}$  is independently a sulfonyl substituent; and

each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is independently an indolyl substituent.

- 125 -


\* \* \*

- 5      35.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>1-7</sub>alkyl, C<sub>3-20</sub>heterocyclyl, or C<sub>5-20</sub>aryl; and is optionally substituted.
36.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>5-20</sub>aryl; and is optionally substituted.
- 10    37.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>5-10</sub>aryl; and is optionally substituted.
38.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>5-10</sub>carboaryl; and is optionally substituted.
- 15    39.    A compound according to claim 34, wherein R<sup>SO</sup> is phenyl or naphthyl; and is optionally substituted.
40.    A compound according to claim 34, wherein R<sup>SO</sup> is naphthyl; and is optionally substituted.
- 20    41.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>5-6</sub>carboaryl; and is optionally substituted.
42.    A compound according to claim 34, wherein R<sup>SO</sup> is C<sub>5-6</sub>aryl; and is optionally substituted.
- 25    43.    A compound according to claim 34, wherein R<sup>SO</sup> is phenyl; and is optionally substituted.
- 30

\* \* \*


- 126 -

44. A compound according to claim 34, wherein  $R^{SO}$  is:



wherein p is an integer from 0 to 5, and each  $R^P$  is a phenyl substituent.

- 5 45. A compound according to claim 34, wherein  $R^{SO}$  is selected from:



wherein q is an integer from 0 to 3; r is an integer from 0 to 4; and each  $R^P$  is a naphthyl substituent.

- 10 46. A compound according to claim 44 or 45, wherein each  $R^P$  is independently selected from:

hydroxy (-OH);

halo;

cyano (-CN);

15 carboxy (-COOH);

azido;

ester;

amino, including:

amino- $C_{1-7}$ alkyl-amino;

20  $C_{1-7}$ alkyl, including:

halo- $C_{1-7}$ alkyl;

amino- $C_{1-7}$ alkyl;

carboxy- $C_{1-7}$ alkyl;

hydroxy- $C_{1-7}$ alkyl;

25  $C_{5-20}$ aryl- $C_{1-7}$ alkyl;

ether, including:

$C_{1-7}$ alkoxy;

halo- $C_{1-7}$ alkoxy;

amino- $C_{1-7}$ alkoxy;

- 127 -

- carboxy-C<sub>1-7</sub>alkoxy;  
hydroxy-C<sub>1-7</sub>alkoxy;  
C<sub>5-20</sub>aryl-C<sub>1-7</sub>alkoxy;  
acyl, including:
- 5 C<sub>1-7</sub>alkyl-acyl;  
halo-C<sub>1-7</sub>alkyl-acyl;  
amino-C<sub>1-7</sub>alkyl-acyl;  
carboxy-C<sub>1-7</sub>alkyl-acyl;  
hydroxy-C<sub>1-7</sub>alkyl-acyl;
- 10 C<sub>5-20</sub>aryl-C<sub>1-7</sub>alkyl-acyl;  
C<sub>5-20</sub>aryl-acyl;  
C<sub>5-20</sub>aryl.
47. A compound according to claim 44 or 45, wherein each R<sup>P</sup> is independently  
15 selected from:
- OH;  
-F, -Cl, -Br, -I;  
-CN;  
20 -COOH;  
-N<sub>3</sub>;  
-COOMe, -COOEt, -COOtBu, -COOPh, -COOCH<sub>2</sub>Ph;
- NH<sub>2</sub>, -NHMe, -NEt, -NMe<sub>2</sub>, -NEt<sub>2</sub>;  
25 piperidino, morpholino, piperazino, N-methyl-piperazino;  
-NH(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -NH(CH<sub>2</sub>)<sub>w</sub>-NHMe, -NH(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -NH(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;
- Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu;  
-CH<sub>2</sub>F, -CH<sub>2</sub>Cl, -CF<sub>3</sub>, -CCl<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -C(CF<sub>3</sub>)<sub>3</sub>;  
30 -(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>w</sub>-NHMe, -(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
-(CH<sub>2</sub>)<sub>w</sub>-COOH;  
-(CH<sub>2</sub>)<sub>w</sub>-OH;  
-CH<sub>2</sub>Ph;

- 128 -

-OMe, -OEt, -OnPr, -OiPr, -OnBu, -OiBu, -OsBu, -OtBu;  
 -OCH<sub>2</sub>F, -OCH<sub>2</sub>Cl, -OCF<sub>3</sub>, -OCCl<sub>3</sub>, -OCF<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OC(CF<sub>3</sub>)<sub>3</sub>;  
 -O(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -O(CH<sub>2</sub>)<sub>w</sub>-NHMe, -O(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>, -O(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
 -O(CH<sub>2</sub>)<sub>w</sub>-COOH;  
 -O(CH<sub>2</sub>)<sub>w</sub>-OH;  
 -OCH<sub>2</sub>Ph;  
  
 -C(=O)Me, -C(=O)Et, -C(=O)-nPr, -C(=O)-iPr, -C(=O)-nBu, -C(=O)-iBu,  
 -C(=O)-sBu, -C(=O)-tBu;  
 -C(=O)CH<sub>2</sub>F, -C(=O)CH<sub>2</sub>Cl, -C(=O)CF<sub>3</sub>, -C(=O)CCl<sub>3</sub>, -C(=O)CF<sub>2</sub>CF<sub>3</sub>,  
 -C(=O)CH<sub>2</sub>CF<sub>3</sub>, -C(=O)C(CF<sub>3</sub>)<sub>3</sub>;  
 -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NH<sub>2</sub>, -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NHMe, -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NMe<sub>2</sub>,  
 -C(=O)(CH<sub>2</sub>)<sub>w</sub>-NEt<sub>2</sub>;  
 -C(=O)(CH<sub>2</sub>)<sub>w</sub>-COOH;  
 -C(=O)(CH<sub>2</sub>)<sub>w</sub>-OH;  
 -C(=O)CH<sub>2</sub>Ph;

-Ph;

wherein w is an integer from 1 to 7.

48. A compound according to claim 44 or 45, wherein each R<sup>P</sup> is independently selected from: -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

49. A compound according to claim 44 or 45, wherein each R<sup>P</sup> is independently selected from: -F, -Me, -OMe.

\*\*\*

50. A compound according to any one of claims 34 to 49, wherein each of R<sup>3N</sup>, R<sup>4N</sup>, R<sup>5N</sup>, R<sup>6N</sup>, and R<sup>7N</sup> is independently -H, or as defined for R<sup>P</sup>.

- 129 -

51. A compound according to any one of claims 34 to 49, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is independently selected from:  
-H, -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

5 52. A compound according to any one of claims 34 to 49, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is independently selected from: -H, -F, -OMe.

\* \* \*

10 53. A compound according to any one of claims 34 to 52, wherein  $R^{3N}$  is -H.

54. A compound according to any one of claims 34 to 52, wherein each of  $R^{4N}$  and  $R^{7N}$  is -H.

15 55. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{4N}$  and  $R^{7N}$  is -H.

56. A compound according to any one of claims 34 to 52, wherein each of  $R^{4N}$ ,  $R^{6N}$ , and  $R^{7N}$  is -H.

20 57. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{6N}$ , and  $R^{7N}$  is -H.

25 58. A compound according to any one of claims 34 to 52, wherein each of  $R^{4N}$ ,  $R^{5N}$ , and  $R^{7N}$  is -H.

59. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ , and  $R^{7N}$  is -H.

30 60. A compound according to any one of claims 34 to 52, wherein each of  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is -H.

- 130 -

61. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is -H.
- 5 62. A compound according to any one of claims 34 to 52, wherein each of  $R^{4N}$ ,  $R^{5N}$ , and  $R^{6N}$  is -H.
63. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ , and  $R^{6N}$  is -H.
- 10 64. A compound according to any one of claims 34 to 52, wherein each of  $R^{3N}$ ,  $R^{4N}$ ,  $R^{5N}$ ,  $R^{6N}$ , and  $R^{7N}$  is -H.
- \* \* \*
- 15 65. Compound SIQ-001 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
66. Compound SIQ-002 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 20 67. Compound SIQ-003 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
68. Compound SIQ-004 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 25 69. Compound SIQ-005 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 30 70. Compound SIQ-006 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.



- 131 -

71. Compound SIQ-007 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

5 72. Compound SIQ-008 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

73. Compound SIQ-009 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

10 74. Compound SIQ-010 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

75. Compound SIQ-011 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

15

76. Compound SIQ-012 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

77. Compound SIQ-013 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

20

\* \* \*

78. A composition comprising a compound according to any one of claims 1 to 77 and a pharmaceutically acceptable carrier or diluent.

25

\* \* \*

78. A compound according to any one of claims 1 to 77 for use in a method of treatment of the human or animal body.

30

\* \* \*

- 132 -

79. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of a proliferative condition.
- 5 80. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of cancer.
81. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of colon cancer or  
10 renal cancer.
82. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of a condition mediated by thioredoxin/thioredoxin reductase.  
15
- \* \* \*
83. A method for the treatment of a proliferative condition comprising administering to a subject suffering from said condition a therapeutically-  
20 effective amount of a compound according to any one of claims 1 to 77.
84. A method for the treatment of cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 77.  
25
85. A method for the treatment of colon cancer or renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 77.
- 30 86. A method for the treatment of a condition mediated by thioredoxin/thioredoxin reductase comprising administering to a subject suffering from said condition a therapeutically-effective amount of a compound according to any one of claims 1 to 77.

- 133 -

\* \* \*

- 5 87. A method of inhibiting thioredoxin/thioredoxin reductase in a cell, *in vitro* or *in vivo*, comprising contacting said cell with an effective amount of according to any one of claims 1 to 77.
- 10 88. A method of regulating cell proliferation, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of a compound according to any one of claims 1 to 77.
- 15 89. A method of (a) inhibiting cell proliferation; (b) inhibiting cell cycle progression; (c) promoting apoptosis; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of a compound according to any one of claims 1 to 77.